Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized trial of standard tacrolimus + mycophenolate versus low-exposure tacrolimus + everolimus in elderly de novo renal transplant recipients
2018-003194-10Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, everolimus and mycophenolate mofetil in immunocompromise (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Successful transplantation (composite primary endpoint). Started Sep 2018; status: active.
02
Drugs
tacrolimuseverolimusmycophenolate mofetil
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2018-003194-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003194-10.